CLOs on the Move

AbbVie

www.abbvie.com

 
At AbbVie, we believe the world needs new approaches to addressing today`s health issues — from life-threatening illness to chronic conditions. We combine advanced science, expertise and passion to solve serious health issues and have a remarkable impact on people`s lives. With 28,000+ employees and medicines in over 170 countries, AbbVie is uniting the best of pharma and the boldness of biotech, to innovate end-to-end approaches that make a real difference in people`s lives.
  • Number of Employees: 5K-10K
  • Annual Revenue: > $1 Billion
  • www.abbvie.com
  • 1 North Waukegan Road
    North Chicago, IL USA 60064
  • Phone: 847.932.7900

Executives

Name Title Contact Details
Arya Sadeghi
 Senior Counsel Profile
Laura Brake
 Associate General Counsel Profile
Matt Bennett
 Head of Sales, Teliso-V Profile
Paul Hammond
 Associate General Counsel Profile
Ying Deng
 Senior Associate General Counsel, Global Profile

Similar Companies

Owl

Better data. Better insights. Better outcomes for behavioral health.

Cornell Communications

Emergency call systems from wireless nurse call systems to wireless emergency response pendants and door monitoring systems

Advanced Pipetting Systems

Advanced Pipetting Systems is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Aurobindo Pharma Limited

Aurobindo Pharma Limited is a pharmaceutical manufacturing company headquartered in HITEC City, Hyderabad, India.

La Jolla Pharmaceutical

La Jolla Pharmaceutical Company is a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases. The Company has several product candidates in development. LJPC-501 is La Jolla`s proprietary formulation of angiotensin II for the potential treatment of catecholamine-resistant hypotension. LJPC-401 is La Jolla`s novel formulation of hepcidin for the potential treatment of conditions characterized by iron overload, such as hereditary hemochromatosis, beta thalassemia, sickle cell disease and myelodysplastic syndrome. LJPC-30S is our next-generation gentamicin derivative program that is focused on therapeutics for the potential treatment of serious bacterial infections as well as rare genetic disorders, such as cystic fibrosis and Duchenne muscular dystrophy.